The Experience of Patients with Endocrine Therapy for Breast Cancer: A Patient Journey Map Based on Qualitative Research - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39451741/
(1) Background: While there is extensive documentation on the medical experience of breast cancer, a thorough understanding of the various stages of endocrine therapy remains insufficient. The aim of this...
This qualitative study mapped breast cancer patients’ experiences during endocrine therapy, revealing evolving coping styles and emotional-behavioral patterns, offering a framework to improve patient-centered care and tailored clinical services.
Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39574178/
Metabolic alterations, a hallmark of cancer, enable tumor cells to adapt to their environment by modulating glucose, lipid, and amino acid metabolism, which fuels rapid growth and contributes to treatment...
Breast cancer cells reprogram metabolism—glucose, lipids, amino acids—driving therapy resistance. Primary and metastatic tumors show distinct metabolic profiles, complicating treatment but presenting targetable vulnerabilities to enhance therapeutic efficacy and outcomes.
Exercise and recovery after surgery in patients with breast cancer: An analysis of the literature - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/38991288/
This review explores the impact of exercise on post-surgical recovery in breast cancer patients. Breast cancer, the most prevalent cancer globally, necessitates treatments beyond conventional modalities such as surgery, chemotherapy,...
This review highlights exercise’s role in post-surgical breast cancer recovery, noting potential quality-of-life benefits. Despite mixed evidence, standardized assessment tools like FACT-B may optimize research, guidelines, and clinical integration.
Understanding genetic variations associated with familial breast cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39390525/
Familial breast cancer has been linked to several genetic diseases and mutations, according to studies. Screening for genetic disorders is recommended by National Comprehensive Cancer Network recommendations. Evaluation of breast...
Familial breast cancer involves high- and moderate-penetrance gene mutations, with BRCA1/2 most frequent. Review highlights 20 genes, 10 syndromes, NCCN screening recommendations, and NGS-driven discoveries enhancing risk assessment.
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40204155/
Palbociclib, ribociclib and abemaciclib have different real-world effectiveness in HR-positive/HER2-negative aBC patients. Our findings can support clinicians in choosing the most appropriate CDK4/6i in specific clinical contexts.
This multicenter real-world study compared CDK4/6 inhibitors in HR+/HER2– advanced breast cancer, showing abemaciclib and ribociclib improved progression-free survival versus palbociclib, with differential benefits across patient subgroups.